Category: Antibodies

Celebrating 100 Partners in the Alloy Biotechnology Ecosystem

Alloy Therapeutics celebrates reaching 100 partners within its global biotechnology ecosystem, a collaborative network designed to democratize access to foundational drug discovery technologies. This diverse community includes academic labs, biotechs, and large pharma companies leveraging shared resources and humanized mouse platforms to accelerate therapeutic development. At Alloy we refer to ourselves as a biotechnology ecosystem […]

Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

Alloy Therapeutics has enhanced its antibody discovery ecosystem by acquiring deepCDR Biologics, integrating advanced bioinformatics and deep learning capabilities into Alloy Discovery Services. This acquisition enables the rapid identification of high-affinity antibody candidates through machine learning-guided protein engineering and proprietary mammalian display technologies. The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery […]

Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases

Alloy Therapeutics and Pyxis Oncology launched Voxall Therapeutics, a joint venture focused on developing novel immune-modulating antibody therapies for cancer and autoimmune diseases. The collaboration integrates Alloy’s ATX-Gx™ discovery platform with Pyxis’ target expertise and preclinical capabilities, facilitated by Alloy’s 82VS venture studio. LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and […]